Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $736,540.07 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the transaction, the director now owns 33,971 shares in the company, valued at $1,463,130.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $45.32 on Friday. The business has a fifty day moving average price of $40.43 and a two-hundred day moving average price of $43.70. The stock has a market capitalization of $2.22 billion, a PE ratio of 15.68, a P/E/G ratio of 0.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92.

Analyst Ratings Changes

AMPH has been the topic of several recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $63.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMPH. TD Asset Management Inc grew its stake in Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after buying an additional 680,976 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Amphastar Pharmaceuticals by 348.7% during the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after acquiring an additional 460,473 shares in the last quarter. Boone Capital Management LLC bought a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $24,740,000. Millennium Management LLC raised its position in Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after purchasing an additional 338,653 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Amphastar Pharmaceuticals during the second quarter worth $9,085,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.